Participated · Series C · Feb 2022

Variantyx develops proprietary, clinically-accredited whole genome analysis platforms for genetic disorders, reproductive health, and precision oncology. The company reports sequencing tens of thousands of genomes to date. It has seen a rapid increase in test volumes in Q1 2024 and is expanding its market share as demand shifts from panel and exome testing to whole genome testing. Variantyx says it maintains strong unit economics while aiming to provide genome-based care to a larger number of patients. The company plans ongoing innovation of new genome analysis technologies and will use new capital for technological and commercial expansion. Variantyx is based in Framingham, Mass., and has attracted more than $125 million in total investment to date. Variantyx develops a proprietary whole-genome analysis platform that provides advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology. Its precision oncology solution combines multiple genomic technologies to identify tumor-specific genetic alterations to help predict therapy response, optimize management, and provide prognostic and clinical-trial information. The company says its platform offers unmatched diagnostic capabilities and improved personalized treatment recommendations. Variantyx is targeting growth in North America and Europe, which it cites as key regions for precision medicine spending. Management intends to scale commercial efforts to take advantage of the growing global precision medicine market. The company recently strengthened its capital position through a debt financing to support that growth. Variantyx is a technology-driven precision medicine company based in Framingham, Mass., providing advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology. The company has developed proprietary whole genome analysis platforms that enable clinicians and patients to understand a person’s genetic makeup. These platforms aim to improve diagnostic capabilities and support personalized treatment recommendations. Led by CEO Haim Neerman, Variantyx provides solutions across diagnostics and oncology markets. The company raised $41.5M in a Series C-2 to accelerate growth and bring newly developed solutions to market. Variantyx plans to focus the investment on expanding its precision oncology offerings while scaling across its other target markets. Variantyx provides Genomic Unity, a WGS-based single-method testing program that identifies multiple variant types from a single patient sample and issues a unified clinical report. The company’s WGS methodology is used to diagnose rare inherited and neurological disorders and is being positioned as a first-line test to reduce the diagnostic odyssey. Variantyx has also announced a WGS-based prenatal test for high-risk pregnancies with ultrasound anomalies. The company recently secured $20M in Series C funding to extend its technology into comprehensive tumor diagnostic solutions and to expand sales. Management says the funding will enable faster diagnosis and implementation of personalized treatment plans for cancer patients. Variantyx operates as a high-complexity hereditary disease testing laboratory under CLIA/CAP.

Led · Equity · Dec 2020

Coagulo Medical Technologies is an MIT‑born startup that has developed a rapid, ultra‑portable point‑of‑care device for comprehensive coagulation diagnostics. The device uses a proprietary approach to parse the entire coagulation cascade, pinpoint deficiencies or inhibition of specific coagulation factors, and quantify their effect on clotting time using only drops of blood within about 10 minutes. Coagulo positions its test as providing clinically actionable, sample‑to‑insight results at the bedside and to supplement traditional tests like prothrombin time and activated partial thromboplastin time. The company licensed technology from MIT and Massachusetts General Hospital and was founded in 2018. Coagulo is based out of Alexandria LaunchLabs. Its point‑of‑care device is not yet approved or cleared by the U.S. Food and Drug Administration; the company says it will accelerate delivery of the platform and meet urgent needs highlighted by COVID‑19.

Participated · Equity · Apr 2020

XRHealth operates state-of-the-art therapeutic care Virtual Rooms built on proprietary FDA- and CE-registered medical extended reality (XR) technology. The platform integrates immersive XR technology, licensed clinicians, and advanced data analytics to provide remote rehabilitation, cognitive assessment and training, and pain management. XRHealth works with several U.S. healthcare providers, hospitals, and rehabilitation centers to deliver treatments in patients' homes. Led by CEO Eran Orr, the company was founded in 2016 and is headquartered in Boston, Massachusetts, with an R&D center in Tel-Aviv, Israel. The company plans to use the new funding to complete its merger with Amelia Virtual Care and to further develop an AI-based clinician to treat mental health conditions and guide physical and occupational therapy programs. XRHealth raised $6M in the reported funding round. XRHealth provides an FDA- and CE-registered extended reality (XR) platform that brings patient care into the Metaverse via therapeutic Virtual Rooms. The company combines proprietary medical virtual and augmented reality technology with licensed clinicians and advanced data analytics to deliver remote rehabilitation, cognitive assessment and pain-management solutions. XRHealth offers a variety of patent-pending therapeutic solutions spanning rehabilitation services, cognitive training and pain management. Following a $10M funding round, the company intends to use the proceeds to expand virtual healthcare treatment in the Metaverse. Founded in 2016 and led by CEO Eran Orr, XRHealth works with several U.S. healthcare providers, hospitals and rehabilitation centers. The company is based in Boston and maintains an R&D center in Tel-Aviv, Israel. XRHealth offers virtual treatment delivered by licensed clinicians using FDA-registered VR applications combined with data analytics. The company operates a virtual clinic that treats patients at home while they are remotely monitored by an XRHealth clinician. Its VR/AR platform includes real and virtual environments, games, and exercises addressing motor, cognitive, and physical symptoms across specialties such as physical, occupational and speech-language therapy, pain and ADHD management, memory/cognitive training, and post-COVID-19 rehabilitation. XRHealth is ISO certified, FDA registered and HIPAA compliant. The company intends to use the new funding to expand sales and marketing to bring VR/AR therapy to patients in the U.S., Australia and Israel. Led by Eran Orr, XRHealth is focused on scaling clinical deployment of its telehealth offerings. XRHealth is a VR telemedicine platform that offers FDA-registered software for remote treatment and rehabilitation. Its clinical applications include rehabilitation for back, shoulder and neck injuries, cognitive training and stress relief, and the company is courting developers to build additional therapeutic content. XRHealth also offers social features to run physician-moderated VR support groups and a web portal for medical professionals to track patient progress and challenges. The company rents hardware directly to consumers, ships Vive Focus and Pico Neo 2 headsets (and supports Oculus hardware), and during COVID-19 is waiving rental fees and working with insurers to waive co-pays. XRHealth said it expected to have more than 500 trained clinicians operating its software by the end of the month, indicating early clinician adoption. Financially, TechCrunch reports XRHealth raised $7 million in new funding, bringing total capital raised to $15 million, including a $4 million seed round in late 2018.

Led · Series A · Feb 2020

EnClear Therapies is a Cambridge, MA–based early-stage neurotechnology company led by CEO Anthony DePasqua. Its flagship product, the EnTrega CSF management platform, is designed to optimize therapeutic delivery and patient care in neuro-oncology and other central nervous system diseases. The company intends to use newly raised funds to expedite development within the Neuro‑Oncology field and to bolster its pre-clinical programs. EnClear has received more than $5M in non-dilutive SBIR funding from NINDS and NCI, which has supported its preclinical progress. It also reports strategic partnerships within the pharmaceutical sector to advance its technology toward clinical application. The company is focused on translating its neurotechnological strategies into improved CNS disease treatments. EnClear Therapies develops a proprietary device-based therapeutic platform that focuses on removing toxic proteins from cerebrospinal fluid (CSF). The company’s system is designed for delivery and monitoring of CSF and aims to aid treatment of neurodegenerative diseases. Its initial product efforts target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). EnClear intends to use new funding to move its therapeutic system into a first-in-human clinical trial in ALS. The company also plans to expand the platform into additional applications and pursue strategic partnerships. EnClear is led by CEO and co-founder Anthony DePasqua and is based in Cambridge, Mass. EnClear Therapies is a Cambridge, MA-based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins and provide closed-loop delivery and monitoring of cerebrospinal fluid (CSF). Its platform aims to treat neurodegenerative diseases by directly clearing pathogenic proteins from CSF while enabling closed-loop therapeutic delivery and monitoring. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). EnClear intends to use the proceeds from its seed financing to advance development of these therapies. In March 2019 it secured approximately $2m in seed funding from several investors. Leadership includes CEO and co-founder Anthony DePasqua and newly hired Kevin Kalish as Vice President of Research and Development.

Participated · Equity · Oct 2019

Verseau Therapeutics is a biotechnology company creating first-in-class macrophage checkpoint modulators to treat cancer and immune/inflammatory diseases. The company focuses on therapies that reprogram macrophages to shift tumors from an immunosuppressive to a pro-inflammatory state. Verseau’s lead program targets PSGL-1 and is designed to reprogram tumor-associated macrophages, activate T cells, and recruit other immune cells to generate an antitumor response. The company licensed an siRNA lipid-nanoparticle delivery technology from the MIT labs of co-founders Dan Anderson and Bob Langer and uses an all‑human translational platform to discover and validate targets. Verseau has validated more than two dozen targets amenable to multiple modalities, including monoclonal antibodies, and is building a pipeline of MCM therapies. It has also appointed George Golumbeski as Chairman and entered a strategic collaboration with 3SBio to commercialize select MCM antibodies in Greater China while retaining global rights.